This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KB-141

Bristol-Myers Squibb Company

Drug Names(s): KB-141

Description: KB-141 is a TR beta agonist. Thyroid hormone receptors (TRs) regulate both body weight and cholesterol levels. However, thyroid hormones also have deleterious effects, particularly on the heart. The TR beta subtype is involved in cholesterol lowering and possibly elevating metabolic rate, whereas TR alpha appears to be more important for control of heart rate (HR).

Deal Structure: In fall 1997, Karo Bio and Bristol-Myers Squibb initiated a drug discovery collaboration to develop novel treatments for obesity and metabolic syndromes.

In April 2004, Bristol-Myers Squibb returned project rights to Karo Bio.

Partners: Karo Bio


KB-141 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug